Erythropoietin (EPO)

Erythropoietin (EPO) is produced primarily by the kidney and is the factor regulating red blood cell (RBC) production in mammals. Renal production of EPO is regulated by changes in oxygen availability. Under conditions of hypoxia, the level of circulating EPO increases, leading to increased production of RBCs. The overproduction of EPO may be an adaptive response associated with conditions that produce tissue hypoxia, such as living at high altitude, chronic obstructive pulmonary disease, cyanotic heart disease, sleep apnea, high-affinity hemoglobinopathy, smoking, or localized renal hypoxia. In other instances, excessive EPO levels result from production by neoplastic cells. Cases of increased EPO production and erythrocytosis have been reported for patients with renal carcinomas, benign renal tumors, Wilms' tumors, hepatomas, liver carcinomas, cerebellar hemangioblastomas, adrenal gland tumors, smooth muscle tumors, and leiomyomas. Deficient levels of EPO production are found in conjunction with certain forms of anemias. These include anemia of renal failure and end-stage renal disease, anemias of chronic disorders, chronic infections, autoimmune diseases, rheumatoid arthritis, AIDS, malignancies, anemia of prematurity, anemia of hypothyroidism, and anemia of malnutrition.

Swiss-Prot Accession Number: P01588


 
 
Publications
Serum Apolipoprotein E and Other Inflammatory Markers Can Identify Non-Responding Patients to a Dendritic Cell Vaccine (2018) Leeman H, Kaminska E, Green D, Bodman-Smith M, Gravett A, Bodman-Smith K, Copier J, Coulton G, Fusi A, Dalgleish AG Translational Oncology
Serum proteomic analysis identifies sex-specific differences in lipid metabolism and inflammation profiles in adults diagnosed with Asperger syndrome (2014) Steeb H, Ramsey JM, Guest PC, Stocki P, Cooper JD, Rahmoune H, Ingudomnukul E, Auyeung B, Ruta L, Baron-Cohen S, Bahn S Mol Autism. 2014 Jan 27;5(1):4
Serum proteomic analysis identifies sex-specific differences in lipid metabolism and inflammation profiles in adults diagnosed with Asperger syndrome (2014) Steeb H, Ramsey JM, Guest PC, Stocki P, Cooper JD, Rahmoune H, Ingudomnukul E, Auyeung B, Ruta L, Baron-Cohen S, Bahn S Mol Autism. 2014 Jan 27;5(1):4
A Canonical Transforming Growth Factor Beta-Dependent Signaling Pathway is Present in Peripheral Blood Cells of Cancer Patients with Skeletal Metastasis (2013) Kadam S, Cleverly AL, Farmen M, Grondin J, Cox YI, Lahn M J Mol Biomark Diagn 2013, 4:3
Identification of Subgroups of Schizophrenia Patients with Changes in Either Immune or Growth Factor and Hormonal Pathways (2013) Schwarz E, Van Beveren NJM, Ramsey J, Leweke FM, Rothermundt M, Bogerts B, Steiner J, Guest PC, Bahn S Schizophrenia Bulletin
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis (2012) Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH Jr, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM N Engl J Med. 2012 Mar;366(9):799-807
Bevacizumab therapy normalizes the pathological intraocular environment beyond neutralizing VEGF (2010) Sharma RK, Rogojina AT, Chalam KV Mol Vi. 16: 2175-2184.
Sex-specific serum biomarker patterns in adults with Asperger's syndrome (2010) Schwarz E, Guest PC, Rahmoune H, Wang L, Levin Y, Ingudomnukul E, Ruta L, Kent L, Spain M, Baron-Cohen S, Bahn S Mol Psychiatry. 2010 Sep 28. [Epub ahead of print]